EC
MIRM icon

EntryPoint Capital’s Mirum Pharmaceuticals MIRM Stock Holding History

EntryPoint Capital’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$476K Hold
5,150
– – 0.14% 272
2025
Q4 		$407K Sell
5,150
-2,728
-35% -$196K 0.16% 240
2025
Q3 		$578K Buy
7,878
+612
+8% +$38.9K 0.22% 122
2025
Q2 		$370K Sell
7,266
-2,409
-25% -$107K 0.19% 197
2025
Q1 		$436K Buy
+9,675
New +$456K 0.2% 152
2024
Q2 		– Sell
-1,668
Closed -$41.9K – 1337
2024
Q1 		$41.9K Sell
1,668
-99
-6% -$2.72K 0.04% 845
2023
Q4 		$52.2K Buy
+1,767
New +$53.5K 0.05% 698

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

EntryPoint Capital's MIRM Position: Q1 2026 in Review

EntryPoint Capital held its Mirum Pharmaceuticals (MIRM) position steady in Q1 2026 at 5,150 shares worth $476K. The position accounts for 0.14% of the portfolio, ranked #272.

EntryPoint Capital first reported a position in MIRM in Q4 2023 and has held it in 7 quarters since. The position peaked at $578K in Q3 2025. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • EntryPoint Capital held 5,150 shares of Mirum Pharmaceuticals worth $476K as of Q1 2026.
  • EntryPoint Capital left its Mirum Pharmaceuticals share count unchanged in Q1 2026.
  • Mirum Pharmaceuticals made up 0.14% of EntryPoint Capital's portfolio in Q1 2026, its #272 holding.
  • EntryPoint Capital first reported a position in Mirum Pharmaceuticals in Q4 2023 and has held it in 7 quarters since.
  • EntryPoint Capital's Mirum Pharmaceuticals position peaked at $578K in Q3 2025.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.